Palatin Technologies (PTNT) Stock Price, News & Analysis

Company Overview

Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that is in Phase 2 clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease, which is in Phase 3 clinical trial; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL8177, an oral peptide formulation for treatment of ulcerative colitis, which entered Phase 2 clinical trials. The company was founded in 1986 and is based in Cranbury, New Jersey.

Key Stats

• Today's Range: N/A
• 50-Day Range: $4.78 to $7.20
• 52-Week Range: N/A
• Volume: 7,665 shs
• Average Volume: 1.17 million shs
• Market Capitalization: $145.66 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $350.00
• Consensus Rating: Buy

Palatin Technologies Stock Analysis - MarketRank™

Palatin Technologies scored higher than 21% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Palatin Technologies has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Palatin Technologies has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Palatin Technologies is -3.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Palatin Technologies is -3.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for PTNT.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Palatin Technologies does not currently pay a dividend.

Dividend Growth

Palatin Technologies does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for PTNT.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

Search Interest

Only 13 people have searched for PTNT on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

2 people have added Palatin Technologies to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Palatin Technologies insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 7.10% of the stock of Palatin Technologies is held by insiders.

Percentage Held by Institutions

Only 11.50% of the stock of Palatin Technologies is held by institutions.

PTNT Stock Analysis - Frequently Asked Questions

How were Palatin Technologies' earnings last quarter?

Palatin Technologies, Inc. (PINK:PTNT) announced its earnings results on Wednesday, May, 15th. The biopharmaceutical company reported ($26.50) earnings per share (EPS) for the quarter, missing the consensus estimate of ($25.00) by $1.50.
Read the conference call transcript.

When did Palatin Technologies' stock split?

Palatin Technologies shares reverse split on the morning of Tuesday, August 12th 2025.The 1-50 reverse split was announced on Tuesday, August 12th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, August 12th 2025. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split.

How do I buy shares of Palatin Technologies?

Shares of PTNT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Last Earnings: 5/15/2024
• Today: 8/22/2025
• Next Earnings (Estimated): 9/29/2025
• Fiscal Year End: 6/30/2026

Industry, Sector and Symbol

• Stock Exchange: PINK
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: PINK:PTNT
• Previous Symbol: NYSEAMERICAN:PTN
• CIK: 911216
• Web: www.palatin.com
• Phone: (609) 495-2200
• Fax: 609-495-2202
• Employees: 30
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Palatin Technologies: $350.00
• High Price Target: $350.00
• Low Price Target: $350.00
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.55)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$29.74 million
• Net Margins: N/A
• Pretax Margin: -1,590.66%
• Return on Equity: N/A
• Return on Assets: -365.57%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.38
• Quick Ratio: 0.38

Sales & Book Value

• Annual Sales: $4.49 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.25) per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 26,010,000
• Free Float: 18,160,000
• Market Cap: $145.66 million
• Optionable: Not Optionable
• Beta: 0.87